Individual Patient Compassionate Use of Fedratinib
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03723148|
Expanded Access Status : Available
First Posted : October 29, 2018
Last Update Posted : September 18, 2020
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib.
Expanded access is only available in markets where fedratinib is not yet approved.
|Condition or disease||Intervention/treatment|
|Myelofibrosis||Drug: Oral Fedratinib|
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|See clinical trials of the intervention/treatment in this expanded access record.|
|Official Title:||Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib|
- Drug: Oral Fedratinib
Oral fedratinib administered as directed by treating physician.Other Name: FEDR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03723148
|Contact: Celgene Medical Informationfirstname.lastname@example.org|
|United States, New Jersey|
|Summit, New Jersey, United States, 07901|